Cegedim Launches Health Data Business in UK

Article

Cegedim has announced the launch of its Health Data Business in support of pharmaceutical companies, clinical research organizations, and academic institutions.

Healthcare technology and services company, Cegedim, has announced the launch of its Health Data Business in support of pharmaceutical companies, clinical research organizations, and academic institutions, in a July 1, 2019 press release.

Customers of Cegedim’s data business will be offered access to more than 56 million anonymized real-world patient records, which are available through The Health Improvement Network (THIN) database. Through these data, it is hoped that companies will be able to drive improvements in patient care and outcomes.

Additionally, Cegedim announced the launch of a cloud-based solution, Health Data Lab, which provides business intelligence and analytics. The data lab uses THIN data alongside predefined calculations around aggregated data to gain an understanding of market trends, or can be used for more specific questions, such as treatment pathways, with bespoke analysis.

“Our THIN database has been a trusted data source, powering advancements in the healthcare industry, for some time. It is one of the most respected and reliable data sources for anonymized patient data,” said Steve Bradley, group managing director, Cegedim UK, in the press release. “We now want to help our customers to think outside the box and further improve patient outcomes by using our expertise and analytical solutions to better understand the wider healthcare economy. Cegedim Health Data and the Health Data Lab have been born from the belief that high data quality, management, and insights are the key to a better way of addressing current patient pathways, trends, and making significant improvements across the healthcare sector.”

Source: Cegedim

 

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content